Advisory Board and Editors Oncology
Matteo Lambrughi
I'm currently a PostDoctoral researcher at the Computational Biology Laboratory at the Danish Cancer Society Research Center, Copenaghen, Denmark.
Brittany N Lasseigne
Brittany N. Lasseigne, PhD is an Assistant Professor of Cell, Developmental and Integrative Biology at The University of Alabama at Birmingham School of Medicine. She trained in Biotechnology, Science, and Engineering at Mississippi State University (B.S.) and the University of Alabama in Huntsville (Ph.D.) and completed a postdoctoral fellowship in genetics and genomics at the HudsonAlpha Institute for Biotechnology.
Her lab develops and applies genomic- and data-driven strategies (including single-cell and long-read sequencing) to discover biological signatures that might be used to improve patient care and provide insight into the cellular and molecular processes contributing to disease, especially for diseases impacting the brain and/or kidney. Their recent work includes prioritizing drug repurposing candidates for cancers and polycystic kidney disease, evaluating preclinical models and cross-species transcriptomic signatures to improve disease modeling, and applying single-cell and long-read technologies to neurological disease tissues to understand the role that context plays in disease etiology, progression, and treatment.
The Lasseigne Lab is currently focused on integrating genomics data, functional annotations, and patient information with machine learning and regulatory network approaches across diseases that impact the brain or kidney to discover novel mechanisms in disease etiology and progression, identify genome-driven therapeutic targets and opportunities for drug repositioning and repurposing, determine clinically-relevant biomarkers, and understand how cellular context contributes to these diseases. Collectively, these distinct projects all apply genetics and genomics to human diseases and build tools to accelerate future research. Their lab also develops data science software and analytical pipelines that are open-source, well-documented, and hosted by third-party code distributors, critical for facilitating reproducibility and enabling the research community to use the methods they develop.
Zhiming Li
Dr. Zhiming Li is an early career researcher at Columbia University. His primary research focus is on epigenetic inheritance and cancer epigenetics, and his long-term goals are to understand the fundamental mechanisms of epigenetic inheritance and how such mechanisms and epigenetic alterations are involved in tumorigenesis, which eventually would allow him to identify druggable targets for cancer intervention.
Ning Li
Prof. Li received his Medical Doctorate in 2005 as an outstanding graduate of the Chinese Union Medical University (CUMU). In the same year, he worked in the Department of Thoracic Surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences, where he served as an attending physician, deputy chief physician, and was appointed Chief Physician in 2019. He has a solid theoretical foundation and excellent research ability, and has accumulated rich clinical experience during my work. In 2017, he took over as the Director of the Office of Drug Clinical Trial Research Center, and his outstanding achievements in the management of clinical trial institutions and clinical and translational research, and is currently served as the chief expert of China GCP platform and Leading PI of international multicenter clinical trials of anti-cancer drug discovery. He is committed to new anti-tumor drug research, real-world research, full chain translation research of clinical trials, precision treatment of rare tumors and tumor big data research. His H-Index is 44 based on Web of Science. As a sub-project leader of the National 973 Major Project, the National Key R&D Program for Precision Medicine, the National Natural Science Foundation of China, the GCP platform leader, and the leader of the 13th and 14th Five-Year Innovation Project, he has undertaken many research projects.
Jiaqi Liang
Dr. Jiaqi Liang is a Researcher in the Department of Thoracic Surgery, Zhongshan Hospital, Fudan University. Her research predominantly focuses on the clinical and molecular research of lung cancer.
Annika Lindblom
Professor in medical genetics, senior consultant at the department of Clinical Genetics Karolinska University Hospital.
Dongliang Liu
Dr. Dongliang Liu is a Postdoctoral Associate in the Department of Surgery at the Baylor College of Medicine. His research interests include: Cancer therapy, especially for pancreatic cancer immunotherapy; Chimeric virus-like particles (VLP) vaccine, especially for cancer vaccines; Novel antibiotics development including antimicrobial peptides; Epitomics and multi-epitope peptide vaccine development for pathogenic viruses.
Enza Lonardo
I obtained my Bachelor in 2003 in Plant Biotechnology at University of Naples Federico II under the supervision of Dr. Roberto Defez at IGB.
In 2008, I obtained my PhD at University of Naples Federico II under the supervision of Dr. Gabriella Minchiotti at IGB working on Cripto signaling in embryonic stem cells.
In 2009 I moved to Madrid where I started my first postdoc in Christopher Heeschen lab at CNIO where I was working on TGF-beta in pancreatic cancer.
In 2012 I moved to Barcelona at IRB as Senior Postdoc in Eduard Batlle lab working on TGF-beta signaling in colorectal cancer.
Since February 2017 I joined the IGB as Group Leader to study the tumor-stroma crosstalk mediated by TGF-beta in gastrointestinal cancer (pancreatic and colorectal).
Weiren Luo
Dr. Luo got Ph.D. degree in Southern Medical University, China (Advisor: Prof. Kaitai Yao, Academician of Chinese Academy of Science), and sponsored by the China Scholarship Council and Shenzhen Goverment, he had been to University of California/Lawrence Berkeley National Laboratory (Bissell MJ's lab, Academician of American Academy of Science), University of Miami and Harvard Medical School, USA as Visiting Scholar/Doctor. He proposed human medical ecology tree , nasopharyngeal carcinoma (NPC) ecology and ecological pathology. The nature of human cancer as multidimensional spatiotemporal "unity of ecology and evolution" pathological ecosystem （Theranostics
. 2023 Mar 5;13(5):1607-1631. ）" Ecological pathology", that is " Apply the ecological (-evolutionary) principles and approaches to study the etiology, pathogenesis, pathological changes and outcomes of human diseases. "
Prof. Luo served as Evaluation Expert of Ministry of Education Degree and Graduate Education (China), Bentham Science Publishers Ambassador, Front Med Associate editor, J Cell Mol Med Associate editor, World J Clin Oncol Editorial board, Journal of Cancer Research Updates Editorial board，and was active to review over 90 journals such as Semin Cancer Biol, J Exp Clin Cancer Res, Cancer Communications, OncoImmunology, Int J Cancer, Histopathology. Additionally, Prof. Luo was invited to take part in Times Higher Education World University Rankings.
Ian J Majewski
My research group is working to identify genetic mutations that contribute to the development of leukaemia, and studying how these mutations influence a patient’s response to therapy. The cancer landscape is both complex and dynamic and we're using genomic approaches to study how cancer cells evolve in response to treatment.
Fabrizio Mattei
Dr. Fabrizio Mattei graduated from University “La Sapienza” in Rome and completed his specialization in biotechnologies and oncology at the same university. In 2000, he became a fellow at the Edward Jenner Institute for Vaccine Research in David Tough's laboratory (Newbury, U.K.), where he acquired experience in the field of dendritic cell immunology. He is currently a Researcher, Group Leader and Principal Investigator at the Istituto Superiore di Sanità (Rome, Italy), where he has focused on the molecular interactions between dendritic cells and type I Interferons signalling.
His current research is aimed at understanding the role of Interferons signalling and IL-33 in the interface between tumor and immune system in both mouse and human models. Furthermore, he is also conducting research aimed at investigating on crosstalk between immune system and cancer by Cell-on-Chip devices. In addition, Dr. Mattei is developing a multidisciplinary laboratory network focused at the realization of Organ-On-Chip platforms, useful to mimic and study human diseases and cancer.
Michal Mego
Dr. Michal Mego is an Associate Professor at the 2nd Department of Medical Oncology, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia. He is also a Head of the Translational Research Unit, National Cancer Institute, Bratislava. Dr. Mego's research interests include Circulating tumor cells, Breast Cancer and Testicular cancer.